Alflutinib mesylate

SKU: orb1300009

Description

Alflutinib mesylate (AST2818 mesylate) is an irreversible EGFR tyrosine kinase inhibitor with high selectivity for mutant forms, including the T790M resistance mutation. It is utilized in preclinical oncology research, demonstrating activity in both cellular assays and animal models of non-small cell lung cancer.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 2130958-55-1
• MW: 664.7
• Purity: 99.81% (May vary between batches)
• Formula: C₂₉H₃₅F₃N₈O₅S
• SMILES: CS(O)(=O)=O.CN(C)CCN(C)c1nc(OCC(F)(F)F)c(Nc2nccc(n2)-c2cn(C)c3ccccc23)cc1NC(=O)C=C
• Target: EGFR
• Solubility: 10% DMSO+40% PEG300+5% Tween-80+45% Saline:1 mg/mL (1.5 mM);DMSO:55 mg/mL (82.74 mM)

Storage & Handling

• Storage: Powder: -20°C for 3 years | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Alflutinib Mesylate, Alflutinib mesylate, Alflutinib, AST 2818, AST 2818 Mesylate, AST2818, AST-2818, AST2818 Mesylate, AST2818 mesylate, AST-2818 Mesylate, cancer, NSCLC, inhibit, Inhibitor, HER1, EGFR, Epidermal growth factor receptor, ErbB-1, Furmonertinib, esistant mutation, T790M

Compound Identifiers

PubChem CID

134828257